Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Feki, Anis; Irminger-Finger, Irmgard

doi:10.1016/j.critrevonc.2004.07.002

Cited by 143Cancer-related Molecular PathwaysBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Feki, Anis, Irminger-Finger, Irmgard·2004·Critical Reviews in Oncology/Hematology

DOI 10.1016/j.critrevonc.2004.07.002

Open this paper in CoChat — free account

Abstract

Breast and ovarian cancers, like other cancers, occur due to genetic damage. Research aimed to determine the specific genes involved in the development of breast and ovarian cancers will help to understand how normal breast and ovarian epithelial cells escape regulation of proliferation, apoptosis and senescence. It was determined that approximately 10% of ovarian cancers and 20-30% of breast cancers arise in women who have inherited mutations in cancer susceptibility genes such as BRCA1, BRCA2 and other DNA repair genes. The ability to perform genetic testing permits the identification of women at increased risk who can then be offered preventive strategies. The vast majority of ovarian and breast cancers are sporadic, presumably resulting from the accumulation of genetic damage over lifetime. Several genes involved in breast and ovarian carcinogenesis have been identified, most notably the p53 tumor suppressor. The recent availability of expression microarrays has facilitated the simultaneous screening of thousands of genes and this will extend further the understanding of molecular events involved in the dynamic development of ovarian and breast cancers. Then, all this knowledge could be translated into effective screening, surveillance, prevention, and treatment strategies in the future.

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2004.07.002

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 mutations are prevalent in numerous cancers, with up to 50% of malignancies harboring p53 mutations.
“Unfortunately, p53 mutations are prevalent in numerous cancers, with up to 50% of malignancies harboring p53 mutations.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [502]
No approved p53-based therapies exist globally due to the absence of a typical drug target.
“Due to the absence of a typical drug target, no approved p53-based therapies exist globally.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [502]

1 retracted

p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao, Z. M., Wu, J., Shen, Z., & Nguyen, M. (2001) · PubMed · Cited by 64 · see citing works
Retracted
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761 · see citing works
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463 · see citing works
Cancer statistics, 1999
Landis, S., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068 · see citing works
Apoptosis
Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00625-6 · Cited by 2,236 · see citing works
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8 · Cited by 2,118 · see citing works
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079 · see citing works
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065 · see citing works
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Fitzgibbons, P. L., Page, D., Weaver, D. L., Thor, A. D., Allred, D. C., Gm, C., Sg, R., O’Malley, F. P., Jf, S., Connolly, J., et al. (2000) · PubMed · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016 · see citing works
Too Many Rodent Carcinogens: Mitogenesis Increases Mutagenesis
Ames, B. N., & Gold, L. S. (1990) · Science · doi:10.1126/science.2136249 · Cited by 770 · see citing works
Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer
Allred, D. C., Clark, G. M., Elledge, R. M., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 769 · see citing works
An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism
Dmitriev, I. P., Krasnykh, V. N., Miller, C. R., Wang, M., Kashentseva, E. A., Mikheeva, G., Belousova, N., & Curiel, D. T. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9706-9713.1998 · Cited by 768 · see citing works
Ovarian cancer: epidemiology, biology, and prognostic factors.
Holschneider, C., & Berek, J. (2000) · Seminars in surgical oncology · doi:10.1002/1098-2388(200007/08)19:1 · Cited by 764 · see citing works
Accumulation of p53 Tumor Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers
Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L. H., Chen, L.-C., Mayall, B. H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.845 · Cited by 721 · see citing works
Signaling to p53
Prives, C. (1998) · Cell · doi:10.1016/s0092-8674(00)81774-2 · Cited by 623 · see citing works
P53 expression in breast cancer
Cattoretti, G., Rilke, F. O., Andreola, S. A., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 597 · see citing works
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53
Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 538 · see citing works
Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies
Whittemore, A. S., Harris, R. B., Itnyre, J., Halpern, J., & the Collaborative Ovarian Cancer Group (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116426 · Cited by 524 · see citing works
A policy framework for commissioning cancer services
Whitehouse, M. R. (1995) · BMJ · doi:10.1136/bmj.310.6992.1425 · Cited by 506 · see citing works
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke‐Pearson, D. L., Iglehart, J. D., Bast, R. C., & Berchuck, A. (1991) · PubMed · Cited by 465 · see citing works
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
Bergh, J. C. S., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 456 · see citing works
Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes.
Hussain, S. P., & Harris, C. C. (1998) · PubMed · Cited by 409 · see citing works
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 351 · see citing works
Prognostic Factors in Breast Cancer.
(1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300170130053 · Cited by 343 · see citing works
Association of Overexpression of Tumor Suppressor Protien p53 With Rapid Cell Proliferation and Poor Prognosis in Node-Negative Breast Cancer Patients
Isola, J., Visakorpi, T., Holli, K. A., & Kallioniemi, O. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.14.1109 · Cited by 341 · see citing works
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326 · see citing works
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
(1991) · BMJ · doi:10.1136/bmj.303.6807.884 · Cited by 298 · see citing works
p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R. L., Merritt, V., Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289 · see citing works
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles, A., Wen, W., Schmider, A., Gee, C., Runnebaum, I. B., Kilian, U., Jones, L. A., El‐Naggar, A. K., Minguillon, C., Schönborn, I., et al. (2001) · PubMed · Cited by 284 · see citing works
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti, S. C., Torre, G. D., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C. E., Cornarotti, M., Oriana, S., et al. (1996) · PubMed · Cited by 276 · see citing works
Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
Stewart, L. A., Aabo, K., Adnitt, P. I., Adams, M., Alberts, D. S., Barley, V., Bell, D. R., Bianchi, U., Blessing, J. A., Buyse, M. E., et al. (1991) · Cited by 270 · see citing works
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
Kanerva, A., Mikheeva, G., Krasnykh, V. N., Coolidge, C. J., Lam, J. T., Mahasreshti, P. J., Barker, S., Straughn, M. J., Barnes, M. N., Alvarez, R. D., et al. (2002) · PubMed · Cited by 255 · see citing works
Ovarian tumors. A review.
Scully, R. E. (1977) · PubMed · Cited by 244 · see citing works
p53 mutations in breast cancer.
Coles, C., Condie, A., Chetty, U., Steel, C., Evans, H. J., & Prosser, J. (1992) · PubMed · Cited by 241 · see citing works
p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients
Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., di Fronzo, G., & Veronesi, U. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.965 · Cited by 237 · see citing works
Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?
Barnes, D. M., DUBLIN, E. A., Fisher, C., Levison, D. A., & Millis, R. R. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90158-d · Cited by 218 · see citing works
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey, G., Me, L., Jc, R., Sj, P., Arboleda, M. J., Shaughnessy, M., Karlan, B. Y., & Dj, S. (1996) · PubMed · Cited by 205 · see citing works
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 196 · see citing works
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187 · see citing works
The p53 tumor suppressor gene frequently is altered in gynecologic cancers
Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R. W., Boyd, J. A., & Bast, R. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70414-7 · Cited by 184 · see citing works
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee, A. G. J., Hollema, H., Suurmeijer, A. J. H., Krans, M., Sluiter, W. J., Willemse, P. H. B., Aalders, J. G., & de Vries, E. G. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.70 · Cited by 184 · see citing works
Spectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke‐Pearson, D. L., Soper, J. T., Bast, R. C., & Berchuck, A. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1513 · Cited by 184 · see citing works
p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study
Ostrowski, J. L., Sawan, A., Henry, L., Wright, C. J., Henry, J. A., Hennessy, C., Lennard, T. W. J., Angus, B., & Horne, C. H. W. (1991) · The Journal of Pathology · doi:10.1002/path.1711640113 · Cited by 180 · see citing works
p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yuluğ, I. G., Peto, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202106 · Cited by 179 · see citing works
p53 mutation is a common genetic event in ovarian carcinoma.
Milner, B. J., Allan, L. A., Eccles, D., Kitchener, H. C., Léonard, R., Kelly, K. F., Parkin, D. E., & Haites, N. E. (1993) · PubMed · Cited by 175 · see citing works
The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
Hamilton, A., & Piccart, M. J. (2000) · Annals of Oncology · doi:10.1023/a:1008390429428 · Cited by 175 · see citing works
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen, P. C., van de Velde, C. J., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroïde, A., van den Broek, L., Sahmoud, T., & van de Vijver, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.470 · Cited by 171 · see citing works
Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer
Iwaya, K., Tsuda, H., Hiraide, H., Tamaki, K., Tamakuma, S., Fukutomi, T., Mukai, K., & Hirohashi, S. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb02710.x · Cited by 171 · see citing works
Radioimmunoassay of the cellular protein p53 in mouse and human cell lines.
Benchimol, S., Pim, D. C., & Crawford, L. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01296.x · Cited by 170 · see citing works
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler, M. F., Kerns, B. J., Humphrey, P. A., Marks, J. R., Bast, R. C., & Berchuck, A. (1993) · PubMed · Cited by 169 · see citing works
Mutations in the p53 gene in primary human breast cancers.
Osborne, R. J., Merlo, G. R., Mitsudomi, T., Venesio, T., Liscia, D. S., Cappa, A. P. M., Chiba, I., Takahashi, T., Nau, M. M., & Callahan, R. (1991) · PubMed · Cited by 163 · see citing works
Prognostic significance of TP53 alterations in breast carcinoma
Andersen, T., Holm, R., Nesland, J. M., Heimdal, K., Ottestad, L., & Børresen‐Dale, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.383 · Cited by 162 · see citing works
TP53 and ovarian cancer
Schuijer, M., & Berns, E. M. J. J. (2003) · Human Mutation · doi:10.1002/humu.10181 · Cited by 160 · see citing works
p53 mutations occur in aggressive breast cancer.
Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., & Theillet, C. G. (1992) · PubMed · Cited by 156 · see citing works
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
Linderholm, B. K., Lindh, B., Tavelin, B., Grankvist, K., & Henriksson, R. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000120)89:1 · Cited by 156 · see citing works
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.
Rovinski, B., & Benchimol, S. (1988) · PubMed · Cited by 156 · see citing works
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study
Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., & Bevilacqua, G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.38 · Cited by 152 · see citing works
Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
Hartmann, L. C., Podratz, K. C., Keeney, G. L., Kamel, N. A. M. H., Edmonson, J. H., Grill, J., su, J., Katzmann, J. A., & Roche, P. C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.64 · Cited by 149 · see citing works
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149 · see citing works
p53 mutations in ovarian cancer: a late event?
Mazars, R., Pujol, P., Maudelondé, T., Jeanteur, P., & Theillet, C. G. (1991) · PubMed · Cited by 148 · see citing works
Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Breyer, B. N., Jiang, W., Cheng, H., Zhou, L., Paul, R., Feng, T., & He, T. (2001) · Current Gene Therapy · doi:10.2174/1566523013348689 · Cited by 146 · see citing works
Prognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006163101948 · Cited by 132 · see citing works
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen, P. P., LESSER, M. L., Arroyo, C. D., Cranor, M. L., Borgen, P. I., & Norton, L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.821 · Cited by 131 · see citing works
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius, S., Børresen‐Dale, A., & Eyfjörd, J. E. (1993) · PubMed · Cited by 119 · see citing works
Identification of BARD1 as Mediator between Proapoptotic Stress and p53-Dependent Apoptosis
Irminger‐Finger, I., Leung, W., Li, J., Dubois‐Dauphin, M., Harb, J., Féki, A., Jefford, C. E., Soriano, J. V., Jaconi, M. E., Montesano, R., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00406-3 · Cited by 116 · see citing works
Self-citation
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., & Giaccone, G. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970529)71:5 · Cited by 112 · see citing works
A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors
Kmet, L. M., Cook, L. S., & Magliocco, A. M. (2003) · Cancer · doi:10.1002/cncr.11064 · Cited by 111 · see citing works
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111 · see citing works
Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
Phillips, N. J., Ziegler, M. R., Radford, D. M., Fair, K., Steinbrueck, T., Xynos, F. P., & Donis-Keller, H. (1996) · PubMed · Cited by 110 · see citing works
Prognostic significance of p53 gene alterations in node-negative breast cancer
Elledge, R. M., Fuqua, S. A. W., Clark, G. M., Pujol, P., Allred, D. C., & McGuire, W. L. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665800 · Cited by 110 · see citing works
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell, S. P., Wilson, P., Derias, N. W., Lane, D. P., & Hall, P. A. (1994) · PubMed · Cited by 110 · see citing works
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei, E., Bogomolniy, F., Federici, M. G., Maresco-Pennisi, D. L., Offit, K., Robson, M. E., Saigo, P. E., & Boyd, J. (1998) · PubMed · Cited by 98 · see citing works
High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy
Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., & Hirohashi, S. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02010.x · Cited by 98 · see citing works
In Vitro Repression of Brca1-associated RING Domain Gene, Bard1, Induces Phenotypic Changes in Mammary Epithelial Cells
Irminger‐Finger, I., Soriano, J. V., Vaudan, G., Montesano, R., & Sappino, A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.5.1329 · Cited by 97 · see citing works
Self-citation
An abundance of p53 null mutations in ovarian carcinoma.
Skilling, J. S., Sood, A. K., Niemann, T., Lager, D. J., & Buller, R. E. (1996) · PubMed · Cited by 97 · see citing works
Accumulation of p53 Protein as a Possible Predictor of Response to Adjuvant Combination Chemotherapy With Cyclophosphamide, Methotrexate, Fluorouracil, and Prednisone for Breast Cancer
Elledge, R. M., Gray, R. J., Mansour, E. G., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K. W., Davidson, N. E., Robert, N., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1254 · Cited by 96 · see citing works
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
Schuyer, M., van der Burg, M. E. L., Henzen-Logmans, S. C., Fieret, J. H., Klijn, J. G. M., Look, M. P., Foekens, J. A., Stoter, G., & Berns, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2101 · Cited by 94 · see citing works
Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53
Beenken, S. W., Grizzle, W. E., Crowe, D. R., Conner, M., Weiss, H. L., Sellers, M. T., Krontiras, H., Urist, M. M., & Bland, K. I. (2001) · Annals of Surgery · doi:10.1097/00000658-200105000-00006 · Cited by 93 · see citing works
Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer
Mano, Y., Kikuchi, Y., Yamamoto, K., Kita, T., Hirata, J., Tode, T., Ishii, K., & Nagata, I. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00124-0 · Cited by 91 · see citing works
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma
Eccles, D., Brett, L., Lessells, A. M., Gruber, L., Lane, D. P., Steel, C., & Leonard, R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.8 · Cited by 91 · see citing works
In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
Tai, Y., Ströbel, T., Kufe, D. W., & Cannistra, S. A. (1999) · PubMed · Cited by 90 · see citing works
Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian Cancer
Baekelandt, M. M. O., Kristensen, G. B., Nesland, J. M., Trope, C. G., & Holm, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2061 · Cited by 88 · see citing works
The prognostic significance of p16INK4a/p14ARF locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
Faderl, S., Kantarjian, H. M., Estey, E. H., Manshouri, T., Chan, C., Elsaied, A. R., Kornblau, S. M., Cortes, J. E., Thomas, D. A., Pierce, S. A., et al. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9 · Cited by 88 · see citing works
Frequent p53 gene mutations and novel alleles in familial breast cancer.
Glebov, O. K., McKenzie, K. E., White, C. A., & Sukumar, S. V. (1994) · PubMed · Cited by 82 · see citing works
Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
Falette, N., Paperin, M.-P., Treilleux, I., Gratadour, A.-C., Peloux, N., Mignotte, H., Tooke, N., Löfman, E., Inganäs, M., Bremond, A. G., et al. (1998) · PubMed · Cited by 82 · see citing works
Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma
Foulkes, W. D., Black, D. M., Solomon, E., Trowsdale, J., & Stamp, G. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540210 · Cited by 82 · see citing works
Adjuvant Systemic Therapy and Survival after Breast Cancer
Olivotto, I. A., Bajdik, C. D., Plenderleith, I. H., Coppin, C., Gelmon, K. A., Jackson, S. M., Ragaz, J., Wilson, K. S., & Worth, A. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301201 · Cited by 82 · see citing works
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
Godwin, A. K., Vanderveer, L., Schultz, D., Lynch, H. T., Altomare, D. A., Buetow, K. H., Daly, M., Getts, L. A., Masny, A., & Rosenblum, N. (1994) · PubMed Central · Cited by 81 · see citing works
Allelic loss on chromosome 17 in human ovarian cancer
Phillips, N. J., Ziegler, M., Saha, B. K., & Xynos, F. P. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540115 · Cited by 81 · see citing works
Racial disparity in the association of p53 gene alterations with breast cancer survival.
Shiao, Y., Chen, V. W., Scheer, W. D., Wu, X., & Corréa, P. (1995) · PubMed · Cited by 76 · see citing works
Genetic Disparity Between Morphologically Benign Cysts Contiguous to Ovarian Carcinomas and Solitary Cystadenomas
Zheng, J., Benedict, W. F., Xu, H., Hu, S., Kim, T. M., Velicescu, M., Wan, M., Cofer, K. F., & Dubeau, L. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1146 · Cited by 75 · see citing works
p53 mutations in ovarian tumors, detected by temperature‐gradient gel electrophoresis, direct sequencing and immunohistochemistry
Kappes, S., Milde‐Langosch, K., Kressin, P., Passlack, B., Dockhorn‐Dworniczak, B., Röhlke, P., & Löning, T. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640111 · Cited by 75 · see citing works
Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell, B. L., Soong, R., Iacopetta, B. J., Seshadri, R., & Smith, D. R. (2000) · PubMed · Cited by 73 · see citing works
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer, M., & Berns, E. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00117-3 · Cited by 73 · see citing works
Rainbow trout p53: cDNA cloning and biochemical characterization
de Fromentel, C. C., Pakdel, F., Chapus, A., Baney, C., May, P., & Soussi, T. (1992) · Gene · doi:10.1016/0378-1119(92)90383-z · Cited by 70 · see citing works
Overexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors
Berchuck, A., Kohler, M. F., Hopkins, M. P., Humphrey, P. A., Robboy, S. J., Rodriguez, G. C., Soper, J. T., Clarke‐Pearson, D. L., & Bast, R. C. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1037 · Cited by 69 · see citing works
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns, E., Klijn, J. G. M., van Putten, W. L., de Witte, H. H., Look, M. P., Gelder, M. E. M., Willman, K., Portengen, H., Benraad, T. J., & Foekens, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.121 · Cited by 69 · see citing works
Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance
Niwa, K., Itoh, M., MURASE, T., Morishita, S., Itoh, N., Mori, H., & Tamaya, T. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.472 · Cited by 68 · see citing works
p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors
Wertheim, I., Muto, M. G., Welch, W. R., Bell, D. A., Berkowitz, R. S., & Mok, S. C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1549 · Cited by 63 · see citing works
p53 gene status and chemosensitivity in ovarian cancer.
Kigawa, J., Sato, S., Shimada, M., Takahashi, M., Itamochi, H., Kanamori, Y., & Terakawa, N. (2001) · PubMed · Cited by 61 · see citing works
Immunophenotype of Ovarian Cancer as Predictor of Clinical Outcome: Evaluation at Primary Surgery and Second-Look Procedure
Goff, B. A., Ries, J., Els, L. P., Coltrera, M. D., & Gown, A. M. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5094 · Cited by 61 · see citing works
p53 mutation does not affect prognosis in ovarian epithelial malignancies
Fallows, S., Price, J., Atkinson, R., Johnston, P. G., Hickey, I., & Russell, S. E. H. (2001) · The Journal of Pathology · doi:10.1002/path.857 · Cited by 61 · see citing works
Organochlorines, p53 mutations in relation to breast cancer risk and survival. A Danish cohort-nested case-controls study
Høyer, A. P., Gerdes, A., Jørgensen, T., Rank, F. E., & Hartvig, H. B. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1013340327099 · Cited by 56 · see citing works
p53 protein overexpression and chemosensitivity in breast cancer
Makris, A., Institut Gustave-Roussy breast cancer group, Powles, T. J., Dowsett, M., Allred, C. D., Mathieu, M., Koscielny, S., Bihan, M. L., Spielmann, M., & Arriagada, R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91014-x · Cited by 56 · see citing works
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Smith‐Sørensen, B., Kærn, J., Holm, R., Dørum, A., Trope, C. G., & Børresen‐Dale, A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.502 · Cited by 54 · see citing works
Molecular aspects of ovarian cancer.
Wenham, R., Lancaster, J., & Berchuck, A. (2002) · Best Practice & Research: Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2002.0298 · Cited by 53 · see citing works
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Casado, E., Gómez-Navarro, J., Yamamoto, M., Adachi, Y., Coolidge, C. J., Arafat, W. O., Barker, S., Wang, M. H., Mahasreshti, P. J., Hemminki, A., et al. (2001) · PubMed · Cited by 51 · see citing works
Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium
Stewart, S. L., Querec, T. D., Gruver, B. N., O'Hare, B., Babb, J. S., & Patriotis, C. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10401 · Cited by 49 · see citing works
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
Ferrandina, G., Fagotti, A., Salerno, M. G., Natali, P. G., Mottolese, M., Maneschi, F., Pasqua, A. D., Benedetti-Panici, P., Mancuso, S., & Scambia, G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690756 · Cited by 47 · see citing works
p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise, S., Chapman, W. B., McLaughlin, J. R., & Andrulis, I. L. (2000) · PubMed · Cited by 46 · see citing works
A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3
Phillips, N. J., Ziegler, M. R., & Deaven, L. L. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04169-9 · Cited by 46 · see citing works
Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
Chevillard, S., Lebeau, J., Pouillart, P., de Toma, C., Beldjord, C., Asselain, B. J. R., Klijanienko, J., Fourquet, A., Magdelénat, H., & Vielh, P. R. (1997) · PubMed · Cited by 46 · see citing works
Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
Jacquemier, J. D., Penault-Llorca, F. M., Viens, P., Houvenaeghel, G. F., Hassoun, J., Torrente, M., Adélaı̈de, J., & Birnbaum, D. (1994) · PubMed · Cited by 44 · see citing works
HTLV-1 infection in a population-based cohort of older persons in Guinea-Bissau, West Africa: Risk factors and impact on survival
Melbye, M., Poulsen, A.-G., Gallo, D., Pedersen, J. B., Biggar, R. J., Larsen, O., Dias, F., & Aaby, P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980504)76:3 · Cited by 42 · see citing works
Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme
Ring, C., Blouin, P., Martin, L.-A., Hurst, H. C., & Lemoine, N. R. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300510 · Cited by 42 · see citing works
The biology of aging
Ershler, W. B., & Longo, D. L. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7 · Cited by 41 · see citing works
Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
Degeorges, A., de Roquancourt, A., Extra, J. M., Espié, M., Bourstyn, E., de Crémoux, P., Soussi, T., & Marty, M. E. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005824216444 · Cited by 40 · see citing works
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
Kučera, E., Speiser, P., Gnant, M., Szabo, L., Samonigg, H., Hausmaninger, H., Mittlböck, M., Fridrik, M., Seifert, M., Kubista, E., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00400-6 · Cited by 37 · see citing works
P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance
Sheridan, E., Silcocks, P. B. S., Smith, J. H. F., Hancock, B. W., & Goyns, M. H. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00325-y · Cited by 37 · see citing works
p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation
Gentile, M., Jungeström, M. B., Olsen, K. E., Söderkvist, P., & Wingren, S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00121-5 · Cited by 37 · see citing works
p53 quantitative immunocytochemical analysis in breast carcinomas*1
Charpin, C. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90032-2 · Cited by 36 · see citing works
Transcriptional Targeting for Ovarian Cancer Gene Therapy
Casado, E., Nettelbeck, D. M., Gómez-Navarro, J., Hemminki, A., Barón, M. G., Siegal, G. P., Barnes, M. N., Alvarez, R. D., & Curiel, D. T. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6305 · Cited by 29 · see citing works
Alteration of Telomerase Activity Associated With Development and Extension of Epithelial Ovarian Cancer
Oishi, T., Kigawa, J., Minagawa, Y., Shimada, M., Takahashi, M., & Terakawa, N. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(98)00044-1 · Cited by 28 · see citing works
p53 mutations in BRCA1-associated familial breast cancer
Schlichtholz, B., Bouchindhomme, B., Pagés, S., Martin, E., Liva, S., Magdelénat, H., Sastre‐Garau, X., Stoppa‐Lyonnet, D., & Soussi, T. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79576-3 · Cited by 27 · see citing works
MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Lizard‐Nacol, S., Genne, P., Coudert, B. P., Riedinger, J., Arnal, M., Sancy, C., Brunet-Lecomte, P., & Fargeot, P. (1999) · PubMed · Cited by 25 · see citing works
BRCA1-p53 relationship in hereditary breast cancer
Sobol, H., Stoppa‐Lyonnet, D., Paillerets, B. B., Peyrat, J. P., Guinebretière, J., Jacquemier, J. D., Eisinger, F., & Birnbaum, D. (1997) · International Journal of Oncology · doi:10.3892/ijo.10.2.349 · Cited by 25 · see citing works
The significance of p53 mutation and over-expression in ovarian cancer prognosis
Allan, L. A., Campbell, M., Milner, B. J., Eccles, D., Leonard, R. C. F., Parkin, D. E., Miller, I. D., Lessells, A. M., Kitchener, H. C., & Haites, N. E. (1996) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.1996.06060483.x · Cited by 24 · see citing works
Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal, E., Gitsch, G., Kohlberger, P., Dadak, C., Miechowiecka, N., & Breitenecker, G. (1992) · PubMed · Cited by 23 · see citing works
The p53 tumor-suppressor gene in human breast cancer
Allred, D. C., Elledge, R. M., Clark, G. M., & Fuqua, S. A. W. (1994) · Cancer treatment and research · doi:10.1007/978-1-4615-2592-9_4 · Cited by 20 · see citing works
Expression of the DF3-P epitope in human ovarian carcinomas.
Ichige, K., Perey, L., Vogel, C.-A., Buchegger, F., & Kufe, D. W. (1995) · PubMed · Cited by 20 · see citing works
Non-surgical aspects of ovarian cancer
Chang, J. C., Bridgewater, J. A., Gore, M. E., Fisher, C., Schofield, J. B., A’Hern, R., Ponder, B. A. J., Jacobs, I. J., McKeage, M. J., Kèlland, L. R., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91168-1 · Cited by 20 · see citing works
p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas
Ioakim‐Liossi, A., Karakitsos, P., Markopoulos, C. J., Aroni, K., Athanassiadou, P., Delivelioti, K., Athanassiades, P. H., & Vaiopoulos, G. (2001) · Cytopathology · doi:10.1046/j.1365-2303.2001.00315.x · Cited by 14 · see citing works
An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis
Leo, A. D., Bajetta, E., Biganzoli, L., Böhm, S., Mariani, L., Ménard, S., Pilotti, S., Fabbiani, M., Gebbia, V., Oriana, S., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00481-5 · Cited by 13 · see citing works
History of ovarian neoplasia: facts and fancy.
Jd, W. (1976) · PubMed · Cited by 11 · see citing works

Flagged first, then by citations

36 of the 172 references couldn’t be matched to a known paper.

Sorted by citations

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982 · see citing works
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · see citing works
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 651 · see citing works
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works
Evading apoptosis in cancer
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 582 · see citing works
Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
p53 and breast cancer, an update
Lacroix, M., Toillon, R., & Leclercq, G. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380 · see citing works
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 364 · see citing works
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · see citing works
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 287 · see citing works
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 257 · see citing works
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240 · see citing works
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · see citing works
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
Ward, C., Langdon, S. P., Mullen, P., Harris, A. L., Harrison, D. J., Supuran, C. T., & Kunkler, I. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.004 · Cited by 181 · see citing works
An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
Wynendaele, J., Böhnke, A., Leucci, E., Nielsen, S. J., Lambertz, I., Hammer, S., Sbrzesny, N., Kubitza, D., Wolf, A. A., Gradhand, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0527 · Cited by 171 · see citing works
Correlation between CpG methylation profiles and hormone receptor status in breast cancers
Feng, W., Shen, L., Wen, S., Rosen, D. G., Jelı́nek, J., Hu, X., Huan, S., Huang, M. L., Liu, J., Şahin, A. A., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1762 · Cited by 154 · see citing works
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 152 · see citing works
Perturbation of Rb, P53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122 · see citing works
Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle‐Teijeiro, J., Medeiros, R., & Schmitt, F. C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-32 · Cited by 114 · see citing works
p53 stability is regulated by diverse deubiquitinating enzymes
Kwon, S., Saindane, M., & Baek, K. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.001 · Cited by 110 · see citing works
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 105 · see citing works
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 102 · see citing works
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91 · see citing works
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Xu, Y., Diao, L., Chen, Y., Liu, Y., Wang, C. Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt011 · Cited by 89 · see citing works
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 89 · see citing works
UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas
Berlingieri, M. T., Pallante, P., Guida, M., Nappi, C., Masciullo, V., Scambia, G., Ferraro, A., Leone, V., Sboner, A., Barbareschi, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210010 · Cited by 78 · see citing works
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77 · see citing works
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Mohammad, R. M., Wu, J., Azmi, A. S., Aboukameel, A., Sosin, A. M., Wu, S., Yang, D., Wang, S., & Al-Katib, A. M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-115 · Cited by 77 · see citing works
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
Klajic, J., Fleischer, T., Dejeux, E., Edvardsen, H., Wärnberg, F., Bukholm, I. K., Lønning, P. E., Solvang, H. K., Børresen‐Dale, A., Tost, J., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-456 · Cited by 74 · see citing works
Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
Wu, J., Vlastos, A., Pelte, M., Caligo, M. A., Bianco, A., Krause, K., Laurent, G. J., & Irminger‐Finger, I. (2005) · International Journal of Cancer · doi:10.1002/ijc.21428 · Cited by 73 · see citing works
Self-citation
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72 · see citing works
A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53
Kurokawa, M., Kim, J., Geradts, J., Matsuura, K., Liu, L., Xu, R., Xia, W., Ribar, T. J., Henao, R., Dewhirst, M. W., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003741 · Cited by 68 · see citing works
Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival
Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67 · see citing works
Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study
Lavigne, J. A., Takahashi, Y., Chandramouli, G. V. R., Liu, H., Perkins, S. N., Hursting, S. D., & Wang, T. T. Y. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9705-6 · Cited by 64 · see citing works
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61 · see citing works
P53 mediated regulation of metallothionein transcription in breast cancer cells
Ostrakhovitch, E. A., Olsson, P., von Hofsten, J., & Cherian, M. G. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21381 · Cited by 62 · see citing works
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 66 · see citing works
Artemisinin Represses Telomerase Subunits and Induces Apoptosis in HPV‐39 Infected Human Cervical Cancer Cells
Mondal, A., & Chatterji, U. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25152 · Cited by 60 · see citing works
Taking Aim at the Undruggable
Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 58 · see citing works
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 58 · see citing works
Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals
Lee, J.-G., Ahn, J., Kim, T. J., Lee, J. H., & Choi, J. (2015) · Scientific Reports · doi:10.1038/srep12642 · Cited by 58 · see citing works
Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas
Moreno, C. S., Matyunina, L. V., Dickerson, E. B., Schubert, N., Bowen, N. J., Logani, S., Benigno, B. B., & McDonald, J. F. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000441 · Cited by 57 · see citing works
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Cybulski, C., Masojc, B., Oszutowska–Mazurek, D., Jaworowska, E., Grodzki, T., Waloszczyk, P., Serwatowski, P., Pankowski, J., Huzarski, T., Byrski, T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn044 · Cited by 57 · see citing works
Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway
Ruan, H., Chen, Y., Niu, X., Zhang, W., Liu, H., Chen, L., Xiong, R., Sun, Q., Jin, C., Liu, Y., et al. (2020) · Chemical Science · doi:10.1039/d0sc04670a · Cited by 55 · see citing works
Synthesis and Evaluation of Thiazolidinone–Pyrazole Conjugates as Anticancer and Antimicrobial Agents
Bhat, M., Poojary, B., Kalal, B. S., Matada, G. S. P., Kabilan, S., Kumar, V., Shruthi, N., Anand, S. A. A., & Pai, V. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0191 · Cited by 55 · see citing works
Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics
Bata, N., & Cosford, N. D. P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00130 · Cited by 55 · see citing works
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia
Kamat, C. D., Green, D. E., Warnke, L. A., Thorpe, J. E., Ceriello, A., & Ihnat, M. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.08.017 · Cited by 53 · see citing works
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Wan, Y., Wu, W., Yin, Z., Guan, P., & Zhou, B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-208 · Cited by 52 · see citing works
A Review of the Ethnic Differences in Breast Cancer
Bowen, R., Stebbing, J., & Jones, L. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.935 · Cited by 50 · see citing works
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer
Neumeister, V. M., Sullivan, C. A. W., Lindner, R. M., Lezon-Geyda, K., Li, J., Závada, J., Martel, M., Glazer, P. M., Tuck, D. P., Rimm, D. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2232-0 · Cited by 48 · see citing works
Molecular predictors of response and outcome in ovarian cancer
Canevari, S., Gariboldi, M., Reid, J. F., Bongarzone, I., & Pierotti, M. A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.03.003 · Cited by 44 · see citing works
miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation
Yang, G., Gong, Y., Wang, Q., Wang, L., & Zhang, X. (2016) · Oncogene · doi:10.1038/onc.2016.270 · Cited by 43 · see citing works
Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes
Xie, B., Nagalingam, A., Kuppusamy, P., Muniraj, N., Langford, P., Győrffy, B., Saxena, N. K., & Sharma, D. (2017) · Scientific Reports · doi:10.1038/srep40070 · Cited by 41 · see citing works
Improved Classification of Epithelial Ovarian Cancer
Steffensen, K. D., Waldstrøm, M., Grove, A., Lund, B., Pallisgaard, N., & Jakobsen, A. K. M. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822a0f6b · Cited by 40 · see citing works
The Sirtuin Inhibitor Tenovin-6 Upregulates Death Receptor 5 and Enhances Cytotoxic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells
Ueno, T., Endo, S., Saito, R., Hirose, M., Hirai, S., Suzuki, H., Yamato, K., & Hyodo, I. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13854886566598 · Cited by 36 · see citing works
Human papillomavirus infection in B owen disease: Negative p53 expression, not p16 INK 4a overexpression, is correlated with human papillomavirus‐associated B owen disease
Murao, K., Yoshioka, R., & Kubo, Y. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12613 · Cited by 35 · see citing works
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation
Montano, X. (2009) · Oncogene · doi:10.1038/onc.2009.143 · Cited by 35 · see citing works
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism
YI, B.-R., CHOI, K. J., KIM, S. U., & CHOI, K.-C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1523 · Cited by 32 · see citing works
Stochastic and Deterministic Models of Cellular p53 Regulation
Leenders, G. B., & Tuszyński, J. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00064 · Cited by 28 · see citing works
Pathologic Aspects of Inflammatory Breast Cancer: Part 2. Biologic Insights Into Its Aggressive Phenotype
Gong, Y. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.11.014 · Cited by 30 · see citing works
Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes
Kallen, J. A., Izaac, A., Chau, S., Wirth, E., Schoepfer, J. G., Mah, R., Schlapbach, A., Stutz, S., Vaupel, A., Guagnano, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900201 · Cited by 30 · see citing works
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Szulc, A., & Woźniak, M. (2024) · Cancers · doi:10.3390/cancers16081483 · Cited by 29 · see citing works
Induction of p53 suppresses chronic myeloid leukemia
Peterson, L. F., Lo, M., Liu, Y., Giannola, D. M., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J., & Talpaz, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272682 · Cited by 24 · see citing works
Molecular Biology of Inflammatory Breast Cancer: Applications to Diagnosis, Prognosis, and Therapy
Wu, M., & Merajver, S. D. (2006) · Breast Disease · doi:10.3233/bd-2006-22104 · Cited by 24 · see citing works
Enhancing the Effects of Low Dose Doxorubicin Treatment by the Radiation in T47D and SKBR3 Breast Cancer Cells
Aghaee, F., Islamian, J. P., Baradaran, B., Mesbahi, A., Mohammadzadeh, M., & Jafarabadi, M. A. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.2.164 · Cited by 23 · see citing works
Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies
Bandaru, S., Ponnala, D., Lakkaraju, C., Bhukya, C. K., Shaheen, U., & Nayarisseri, A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3759 · Cited by 22 · see citing works
FOXA1 positively regulates gene expression by changing gene methylation status in human breast cancer MCF-7 cells.
Zheng, L., Qian, B., Tian, D., Tang, T., Wan, S., Wang, L., Zhu, L., & Geng, X. (2015) · Europe PMC (PubMed Central) · Cited by 22 · see citing works
Indolo‐pyrido‐isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53‐miR34a axis
Avtanski, D. B., Nagalingam, A., Tomaszewski, J. E., Risbood, P. A., Difilippantonio, M. J., Saxena, N. K., Malhotra, S. V., & Sharma, D. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.003 · Cited by 20 · see citing works
Genetic Determinants of Aggressive Breast Cancer
Ventura, A. C., & Merajver, S. D. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.060106.184830 · Cited by 20 · see citing works
S‐MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia
Liu, L., Fan, L., Cheng, F., Zou, Z., Yang, S., Zhang, L., Li, J., & Xu, W. (2012) · Cancer Science · doi:10.1111/cas.12008 · Cited by 20 · see citing works
Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Ivanenkov, Y. A., Kukushkin, M. E., Beloglazkina, A. A., Shafikov, R. R., Barashkin, A. A., Ayginin, A. A., Serebryakova, M. S., Majouga, A. G., Skvortsov, D. A., Тафеенко, В. А., et al. (2023) · Molecules · doi:10.3390/molecules28031325 · Cited by 19 · see citing works
Biology and management of inflammatory breast cancer
Dawood, S. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.90 · Cited by 19 · see citing works
New targets for the treatment of follicular lymphoma
Tageja, N., Padheye, S., Dandawate, P. R., Al-Katib, A. M., & Mohammad, R. M. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-50 · Cited by 19 · see citing works
Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics
Wang, F., Li, Y., Ma, Z., Wang, X., & Wang, Y. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1041-4 · Cited by 18 · see citing works
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas
Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18 · see citing works
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17 · see citing works
Computational Investigation on the p53–MDM2 Interaction Using the Potential of Mean Force Study
Das, P., & Mattaparthi, V. S. K. (2020) · ACS Omega · doi:10.1021/acsomega.9b03372 · Cited by 16 · see citing works
p53 Expression in MCF7, T47D and MDA-MB 468 Breast Cancer Cell Lines Treated with Adriamycin Using RT-PCR and Immunocytochemistry
Kaabinejadian, S., Fouladdel, S., Ramezani, M., & Azizi, E. (2008) · Journal of Biological Sciences · doi:10.3923/jbs.2008.380.385 · Cited by 16 · see citing works
Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis
Oncul, S., & Ercan, A. (2017) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000268 · Cited by 16 · see citing works
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 16 · see citing works
Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction
Pettersson, M., Quant, M., Min, J., Iconaru, L. I., Kriwacki, R. W., Waddell, M. B., Guy, R. K., Luthman, K., & Grøtli, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137867 · Cited by 15 · see citing works
Analysis and Design of Piezoelectric Braille Display
Smithmaitrie, P. (2009) · InTech eBooks · doi:10.5772/7391 · Cited by 12 · see citing works
USP19 Negatively Regulates p53 and Promotes Cervical Cancer Progression
Tyagi, A., Karapurkar, J. K., Colaco, J. C., Sarodaya, N., Antao, A. M., Kaushal, K., Haq, S., Chandrasekaran, A. P., Das, S., Singh, V., et al. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00814-y · Cited by 11 · see citing works
Immunohistochemical study of p53 and Ki67 in a group of patients with mammary carcinoma.
Pleşan, D. M., Georgescu, C. V., Pătrană, N., Pleşan, C., & Stoica, D. (2010) · PubMed · Cited by 11 · see citing works
A Case-Control Study of TP53 R72P Polymorphism in the Breast Cancer Patients of Ethnic Kashmiri Population
Syeed, N. (2010) · World Journal of Oncology · doi:10.4021/wjon261w · Cited by 11 · see citing works
MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri, N. M., Ragab, S. H., Rasheed, M. A., El-Saadany, Z. A., & El-Fattah, S. N. A. (2014) · PubMed · Cited by 11 · see citing works
Molecular and Cellular Biology
Stevenson, M. A., & Calderwood, S. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00002-2 · Cited by 11 · see citing works
Epistatic interaction of Arg72Pro TP53 and −710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival
Rodrigues, P., Furriol, J., Tormo, E., Ballester, S., Lluch, A. M., & Eroles, P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1640-8 · Cited by 10 · see citing works
Molecular and Cellular Biology
Stevenson, M. A., & Calderwood, S. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00002-x · Cited by 9 · see citing works
Modern approach of breast cancer diagnostics
TAMKOVICH, S. N., Voytsitskiy, V. E., & Laktionov, P. P. (2014) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20146002141 · Cited by 8 · see citing works
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 8 · see citing works
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
Omar, S. I., & Tuszyński, J. A. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12480 · Cited by 8 · see citing works
Small‐molecule MDM2 inhibitor LQFM030‐induced apoptosis in p53‐null K562 chronic myeloid leukemia cells
Ribeiro, H. D. O., Cortez, A. P., de Ávila, R. I., da Silva, A. C. G., de Carvalho, F. S., Menegatti, R., Lião, L. M., & Valadares, M. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12540 · Cited by 8 · see citing works
Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?Preprint
Sukhbaatar, N., Bachmayr-Heyda, A., Auer, K., Aust, S., Deycmar, S., Horvat, R., & Pils, D. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001461 · Cited by 8 · see citing works
Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions
Martins, M. B., Batista, F. D. A., Marcello, M. A., Búfalo, N. E., Peres, K. C., Morari, E. C., Soares, F. A., Vassallo, J., & Ward, L. S. (2021) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2021.151766 · Cited by 7 · see citing works
PROGNOSTIC STATUS OF p53 PROTEIN ACCUMULATION IN CANINE MALIGNANT MAMMARY TUMOURS
Łopuszyński, W., Szczubiał, M., & Komsta, R. (2010) · Cited by 7 · see citing works
Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors
Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01780f · Cited by 7 · see citing works
Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes
Niemantsverdriet, M., Jongmans, W., & Backendorf, C. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.07.016 · Cited by 7 · see citing works

Molecular aspects of ovarian cancer.
Wenham, R., Lancaster, J., & Berchuck, A. (2002) · Best Practice & Research: Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2002.0298 · Cited by 53 · see citing works
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Aghmesheh, M., Nesland, J. M., Kærn, J., Dørum, A., Edwards, L. S., Byth, K., Friedlander, M. L., Jackson, P., Tucker, K., & Russell, P. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.035 · Cited by 8 · see citing works
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller, R. E., Lallas, T. A., Shahin, M. S., Sood, A. K., Hatterman‐Zogg, M. A., Anderson, B. O., Sorosky, J. I., & Kirby, P. (2001) · PubMed · Cited by 32 · see citing works
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer, R. P., Shaw, P. A., Verheijen, R. H. M., Ryan, A., Berchuck, A., Ponder, B. A. J., Risch, H. A., McLaughlin, J. R., Narod, S. A., Menko, F. H., et al. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.5.372 · Cited by 45 · see citing works
The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose, S. L., & Buller, R. E. (2002) · PubMed · Cited by 7 · see citing works

Authors: Feki, A., & Irminger-Finger, I.
Venue: Critical Reviews in Oncology/Hematology
Publisher: Elsevier BV
Published: 2004-11
Volume: 52
Issue: 2
Pages: 103-116
ISSN: 1040-8428 (ISSN-L)
DOI: 10.1016/j.critrevonc.2004.07.002
OpenAlex: W2071475683
Cited by: 139
References: 172
Citations by year: 2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 13 · 2014: 7 · 2013: 12 · 2012: 9
FWCI: 0.57
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Critical Reviews in Oncology/Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords: TP53 mutation, mutation spectrum, breast cancer, ovarian cancer, tumor suppressor, BRCA1, BRCA2, hereditary cancer predisposition, sporadic cancer, carcinogenesis, DNA repair genes, genetic testing, cancer prevention
MeSH terms: Breast Neoplasms, Family Health, Female, Gene Frequency, Humans, Mutation, Ovarian Neoplasms, Prognosis, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks